Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228833 | 0.99 | ESR1 (0.51) | ESR1ESR2DRD2DRD3SIGMAR1 | |
| SCHEMBL224248 | 0.88 | ESR1 (0.53) | ESR1ESR2DRD2DRD3SIGMAR1 | |
| SCHEMBL227649 | 0.87 | ESR1 (0.53) | ESR1ESR2SIGMAR1 | |
| SCHEMBL224740 | 0.87 | ESR1 (0.56) | ESR1ESR2DRD2DRD3SIGMAR1 | |
| SCHEMBL225127 | 0.87 | ESR1 (0.53) | ESR1ESR2SIGMAR1 | |
| SCHEMBL225574 | 0.86 | ESR1 (0.61) | ESR1ESR2DRD2DRD3DRD4 | |
| SCHEMBL228940 | 0.85 | ESR1 (0.58) | ESR1ESR2 | |
| SCHEMBL226484 | 0.85 | ESR1 (0.58) | ESR1ESR2 | |
| SCHEMBL227477 | 0.84 | ESR1 (0.49) | ESR1ESR2DRD2DRD3SIGMAR1 | |
| SCHEMBL226263 | 0.83 | ESR1 (0.49) | ESR1ESR2DRD2DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885DRD2 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.